
    
      Dose-escalation, multidose study of MDX-1411, a fully human nonfucosylated monoclonal
      antibody (mAb) targeting the CD70 transmembrane cell-surface protein, which is highly
      expressed in B-cell malignancies such as CLL and MCL.
    
  